# US 2026/0256924 A1 · Indocyanine green (icg) modification for treatment of liver cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0256924 A1
- Document ID: US20260256924A1
- Status: Published application
- Kind: A1
- Application number: 18/877,812
- Filed: 2023-06-23
- Published: 2026-09-03
- Earliest claimed: 2022-06-23
- Assignees: Children's Medical Center Corporation
- Applicants: The Children's Medical Center Corporation
- Inventors: Khashayar Vakili
- Web page: https://patentgrep.com/patent/US20260256924A1

## CPC

- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61K 51/0446: {having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil}
- A61K 51/0497: {conjugates with a carrier being an organic compounds}
- A61P 35/00: Antineoplastic agents
- C07B 59/002: {Heterocyclic compounds}
- C07D 209/60: Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
- C09B 23/086: {more than five >CH- groups}
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C09B: ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES {, e.g. PIGMENTS}; MORDANTS; LAKES (fermentation or enzyme using processes to synthesise a desired chemical compound C12P)

## Abstract

The present disclosure provides compounds of Formula (I) and (I′), which are derivatives of indocyanine green (ICG), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, and prodrugs thereof. The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, or prodrugs thereof, and methods of diagnosing, treating, or preventing diseases by administering to a subject in need thereof the compounds, or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, or prodrugs thereof, or pharmaceutical compositions thereof. The present disclosure also provides methods of preparation of compounds of Formula (I) and (I′).

## Claims

### Claim 1

A compound of Formula I:
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof, wherein:
L is a linker;
R1 is halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —CN, —ORA, —SCN, —SRA, —SSRA, —N3, —NO, —N(RA)2, —NO2, —C(═O)RA, —C(═O)ORA, —C(═O)SRA, —C(═O)N(RA)2, —C(═NRA)RA, —C(═NRA)ORA, —C(═NRA)SRA, —C(═NRA)N(RA)2, —S(═O)RA, —S(═O)ORA, —S(═O)SRA, —S(═O)N(RA)2, —S(═O)2RA, —S(═O)2ORA, —S(═O)2SRA, —S(═O)2N(RA)2, —OC(═O)RA, —OC(═O)ORA, —OC(═O)SRA, —OC(═O)N(RA)2, —OC(═NRA)RA, —OC(═NRA)ORA, —OC(═NRA)SRA, —OC(═NRA)N(RA)2, —OS(═O)RA, —OS(═O)ORA, —OS(═O)SRA, —OS(═O)N(RA)2, —OS(═O)2RA, —OS(═O)2ORA, —OS(═O)2SRA, —OS(═O)2N(RA)2, —ON(RA)2, —SC(═O)RA, —SC(═O)ORA, —SC(═O)SRA, —SC(═O)N(RA)2, —SC(═NRA)RA, —SC(═NRA)ORA, —SC(═NRA)SRA, —SC(═NRA)N(RA)2, —NRAC(═O)RA, —NRAC(═O)ORA, —NRAC(═O)SRA, —NRAC(═O)N(RA)2, —NRAC(═NRA)RA, —NRAC(═NRA)ORA, —NRAC(═NRA)SRA, —NRAC(═NRA)N(RA)2, —NRAS(═O)RA, —NRAS(═O)ORA, —NRAS(═O)SRA, —NRAS(═O)N(RA)2, —NRAS(═O)2RA, —NRAS(═O)2ORA, —NRAS(═O)2SRA, —NRAS(═O)2N(RA)2, —Si(RA)3, —Si(RA)2ORA, —Si(RA)(ORA)2, —Si(ORA)3, —OSi(RA)3, —OSi(RA)2ORA, —OSi(RA)(ORA)2, —OSi(ORA)3, or —B(ORA)2, and contains at least one radioisotope;
each occurrence of RA is independently hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two occurrences of RA are joined together with their intervening atom to form an optionally substituted heterocyclic ring or optionally substituted heteroaryl ring; and
each occurrence of R2 is independently hydrogen, halogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two occurrences of R2 are joined together with their intervening atom to form an optionally substituted carbocyclic ring or optionally substituted heterocyclic ring.

### Claim 2

A compound of Formula I′:
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof, wherein:
L is a linker;
R1 is halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —CN, —ORA, —SCN, —SRA, —SSRA, —N3, —NO, —N(RA)2, —NO2, —C(═O)RA, —C(═O)ORA, —C(═O)SRA, —C(═O)N(RA)2, —C(═NRA)RA, —C(═NRA)ORA, —C(═NRA)SRA, —C(═NRA)N(RA)2, —S(═O)RA, —S(═O)ORA, —S(═O)SRA, —S(═O)N(RA)2, —S(═O)2RA, —S(═O)2ORA, —S(═O)2SRA, —S(═O)2N(RA)2, —OC(═O)RA, —OC(═O)ORA, —OC(═O)SRA, —OC(═O)N(RA)2, —OC(═NRA)RA, —OC(═NRA)ORA, —OC(═NRA)SRA, —OC(═NRA)N(RA)2, —OS(═O)RA, —OS(═O)ORA, —OS(═O)SRA, —OS(═O)N(RA)2, —OS(═O)2RA, —OS(═O)2ORA, —OS(═O)2SRA, —OS(═O)2N(RA)2, —ON(RA)2, —SC(═O)RA, —SC(═O)ORA, —SC(═O)SRA, —SC(═O)N(RA)2, —SC(═NRA)RA, —SC(═NRA)ORA, —SC(═NRA)SRA, —SC(═NRA)N(RA)2, —NRAC(═O)RA, —NRAC(═O)ORA, —NRAC(═O)SRA, —NRAC(═O)N(RA)2, —NRAC(═NRA)RA, —NRAC(═NRA)ORA, —NRAC(═NRA)SRA, —NRAC(═NRA)N(RA)2, —NRAS(═O)RA, —NRAS(═O)ORA, —NRAS(═O)SRA, —NRAS(═O)N(RA)2, —NRAS(═O)2RA, —NRAS(═O)2ORA, —NRAS(═O)2SRA, —NRAS(═O)2N(RA)2, —Si(RA)3, —Si(RA)2ORA, —Si(RA)(ORA)2, —Si(ORA)3, —OSi(RA)3, —OSi(RA)2ORA, —OSi(RA)(ORA)2, —OSi(ORA)3, or —B(ORA)2;
each occurrence of RA is independently hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two occurrences of RA are joined together with their intervening atom to form an optionally substituted heterocyclic ring or optionally substituted heteroaryl ring; and
each occurrence of R2 is independently hydrogen, halogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two occurrences of R2 are joined together with their intervening atom to form an optionally substituted carbocyclic ring or optionally substituted heterocyclic ring.

### Claim 3

The compound of any one of the preceding claims, wherein the compound is of Formula I-a-i, Formula I-a-ii, or Formula I-a-iii:
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof.

### Claim 4

The compound of any one of the preceding claims, wherein the compound is of Formula I-b:
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof, wherein:
each occurrence of Y1 is independently C(RE1)2, NRE2, or —O—;
each occurrence of RE1 is independently hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —CN, —ORA, —SCN, —SRA, —SSRA, —N3, —NO, —N(RA)2, —NO2, —C(═O)RA, —C(═O)ORA, —C(═O)SRA, —C(═O)N(RA)2, —C(═NRA)RA, —C(═NRA)ORA, —C(═NRA)SRA, —C(═NRA)N(RA)2, —S(═O)RA, —S(═O)ORA, —S(═O)SRA, —S(═O)N(RA)2, —S(═O)2RA, —S(═O)2ORA, —S(═O)2SRA, —S(═O)2N(RA)2, —OC(═O)RA, —OC(═O)ORA, —OC(═O)SRA, —OC(═O)N(RA)2, —OC(═NRA)RA, —OC(═NRA)ORA, —OC(═NRA)SRA, —OC(═NRA)N(RA)2, —OS(═O)RA, —OS(═O)ORA, —OS(═O)SRA, —OS(═O)N(RA)2, —OS(═O)2RA, —OS(═O)2ORA, —OS(═O)2SRA, —OS(═O)2N(RA)2, —ON(RA)2, —SC(═O)RA, —SC(═O)ORA, —SC(═O)SRA, —SC(═O)N(RA)2, —SC(═NRA)RA, —SC(═NRA)ORA, —SC(═NRA)SRA, —SC(═NRA)N(RA)2, —NRAC(═O)RA, —NRAC(═O)ORA, —NRAC(═O)SRA, —NRAC(═O)N(RA)2, —NRAC(═NRA)RA, —NRAC(═NRA)ORA, —NRAC(═NRA)SRA, —NRAC(═NRA)N(RA)2, —NRAS(═O)RA, —NRAS(═O)ORA, —NRAS(═O)SRA, —NRAS(═O)N(RA)2, —NRAS(═O)2RA, —NRAS(═O)2ORA, —NRAS(═O)2SRA, —NRAS(═O)2N(RA)2, —Si(RA)3, —Si(RA)2ORA, —Si(RA)(ORA)2, —Si(ORA)3, —OSi(RA)3, —OSi(RA)2ORA, —OSi(RA)(ORA)2, —OSi(ORA)3, or —B(ORA)2, or two occurrences of RE1 are optionally joined together with the intervening atoms to form an optionally substituted cyclic moiety;
each occurrence of RE2 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —C(═O)RA, —C(═O)ORA, —C(═O)SRA, —C(═O)N(RA)2, —C(═NRA)RA, —C(═NRA)ORA, —C(═NRA)SRA, —C(═NRA)N(RA)2, —S(═O)RA, —S(═O)ORA, —S(═O)SRA, —S(═O)N(RA)2, —S(═O)2RA, —S(═O)2ORA, —S(═O)2SRA, —S(═O)2N(RA)2, or a nitrogen protecting group, or two occurrences of RE2 are optionally joined together with their intervening atoms to form an optionally substituted cyclic moiety; and
m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

### Claim 5

The compound of any one of the preceding claims, wherein the compound is of Formula I-b-i:
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof.

### Claim 6

The compound of any one of the preceding claims, wherein the compound is of Formula I-c:
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof.

### Claim 7

The compound of any one of the preceding claims, wherein the compound is of Formula I-c-i:
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof.

### Claim 8

The compound of any one of the preceding claims, wherein the compound is of Formula I-d:
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof.

### Claim 9

The compound of any one of the preceding claims, wherein the compound is of Formula I-d-i:
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof.

### Claim 10

The compound of any one of the preceding claims, wherein each occurrence of RA is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.

### Claim 11

The compound of any one of the preceding claims, wherein at least one occurrence of RA is optionally substituted alkyl.

### Claim 12

The compound of any one of the preceding claims, wherein at least one occurrence of RA is alkyl substituted with one or more optionally substituted amino groups.

### Claim 13

The compound of any one of the preceding claims, wherein at least one occurrence of RA is alkyl substituted with one or more acyl groups.

### Claim 14

The compound of any one of the preceding claims, wherein at least one occurrence of RA is alkyl substituted with halogen.

### Claim 15

The compound of any one of the preceding claims, wherein at least one occurrence of RA is alkyl substituted with fluorine.

### Claim 16

The compound of any one of the preceding claims, wherein at least one occurrence of RA is alkyl substituted with 18F.

### Claim 17

The compound of any one of the preceding claims, wherein the compound is of Formula I-e:
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof, wherein:
each occurrence of RB is independently hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group, or two occurrences of RB are joined together with their intervening atom to form an optionally substituted heterocyclic ring or optionally substituted heteroaryl ring; and
n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

### Claim 18

The compound of any one of the preceding claims, wherein the compound is of Formula I-e-i:
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof.

### Claim 19

The compound of any one of the preceding claims, wherein the compound is of Formula I-f:
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof.

### Claim 20

The compound of any one of the preceding claims, wherein the compound is of Formula I-f-i:
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof.

### Claim 21

The compound of any one of the preceding claims, wherein the compound is of Formula I-g:
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof, wherein:
Rb1 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.

### Claim 22

The compound of any one of the preceding claims, wherein the compound is of Formula I-g-i:
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof.

### Claim 23

The compound of any one of the preceding claims, wherein Rb1 is optionally substituted aryl or optionally substituted heteroaryl.

### Claim 24

The compound of any one of the preceding claims, wherein Rb1 is aryl substituted with halogen.

### Claim 25

The compound of any one of the preceding claims, wherein Rb1 is aryl substituted with fluorine.

### Claim 26

The compound of any one of the preceding claims, wherein Rb1 is aryl substituted with 18F.

### Claim 27

The compound of any one of the preceding claims, wherein Rb1 is heteroaryl substituted with halogen.

### Claim 28

The compound of any one of the preceding claims, wherein Rb1 is heteroaryl substituted with fluorine.

### Claim 29

The compound of any one of the preceding claims, wherein Rb1 is heteroaryl substituted with 18F.

### Claim 30

The compound of any one of the preceding claims, wherein the compound is of Formula I-h:
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof, wherein:
R3 is halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —CN, —ORC, —SCN, —SRC, —SSRC, —N3, —NO, —N(RC)2, —NO2, —C(═O)RC, —C(═O)ORC, —C(═O)SRC, —C(═O)N(RC)2, —C(═NRC)RC, —C(═NRC)ORC, —C(═NRC)SRC, —C(═NRC)N(RC)2, —S(═O)RC, —S(═O)ORC, —S(═O)SRC, —S(═O)N(RC)2, —S(═O)2RC, —S(═O)2ORC, —S(═O)2SRC, —S(═O)2N(RC)2, —OC(═O)RC, —OC(═O)ORC, —OC(═O)SRC, —OC(═O)N(RC)2, —OC(═NRC)RC, —OC(═NRC)ORC, —OC(═NRC)SRC, —OC(═NRC)N(RC)2, —OS(═O)RC, —OS(═O)ORC, —OS(═O)SRC, —OS(═O)N(RC)2, —OS(═O)2RC, —OS(═O)2ORC, —OS(═O)2SRC, —OS(═O)2N(RC)2, —ON(RC)2, —SC(═O)RC, —SC(═O)ORC, —SC(═O)SRC, —SC(═O)N(RC)2, —SC(═NRC)RC, —SC(═NRC)ORC, —SC(═NRC)SRC, —SC(═NRC)N(RC)2, —NRCC(═O)RC, —NRCC(═O)ORC, —NRCC(═O)SRC, —NRCC(═O)N(RC)2, —NRCC(═NRC)RC, —NRCC(═NRC)ORC, —NRCC(═NRC)SRC, —NRCC(═NRC)N(RC)2, —NRCS(═O)RC, —NRCS(═O)ORC, —NRCS(═O)SRC, —NRCS(═O)N(RC)2, —NRCS(═O)2RC, —NRCS(═O)2ORC, —NRCS(═O)2SRC, —NRCS(═O)2N(RC)2, —Si(RC)3, —Si(RC)2ORC, —Si(RC) (ORC)2, —Si(ORC)3, —OSi(RC)3, —OSi(RC)2ORC, —OSi(RC) (ORC)2, —OSi(ORC)3, or —B(ORC)2;
each occurrence of RC is independently hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or two occurrences of RC are joined together with their intervening atom to form an optionally substituted heterocyclic ring or optionally substituted heteroaryl ring; and
p is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

### Claim 31

The compound of any one of the preceding claims, wherein the compound is of Formula I-h-i:
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof.

### Claim 32

The compound of any one of the preceding claims, wherein R3 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.

### Claim 33

The compound of any one of the preceding claims, wherein R3 is optionally substituted heterocyclyl.

### Claim 34

The compound of any one of the preceding claims, wherein R3 is an optionally substituted azacyclooctyne.

### Claim 35

The compound of any one of the preceding claims, wherein R3 is an optionally substituted aza-dibenzocyclooctyne.

### Claim 36

The compound of any one of the preceding claims, wherein the compound is of Formula I-h-ii or I-h-iii:
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof, wherein:
Rc1 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.

### Claim 37

The compound of any one of the preceding claims, wherein Rc1 is optionally substituted alkyl.

### Claim 38

The compound of any one of the preceding claims, wherein Rc1 is alkyl substituted with halogen.

### Claim 39

The compound of any one of the preceding claims, wherein Rc1 is alkyl substituted with fluorine.

### Claim 40

The compound of any one of the preceding claims, wherein Rc1 is alkyl substituted with 18F.

### Claim 41

The compound of any one of the preceding claims, wherein the compound is of Formula
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof, wherein:
R4 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.

### Claim 42 (depends on 41)

The compound of claim 41, wherein R4 is optionally substituted aryl.

### Claim 43 (depends on 41, 42)

The compound of claim 41 or 42, wherein R4 is phenyl substituted with optionally substituted alkyl substituted with optionally substituted heterocyclyl.

### Claim 44 (depends on 41, 42, 43)

The compound of any of claims 41-43, wherein R4 comprises a chelating moiety.

### Claim 45 (depends on 41, 42, 43, 44)

The compound of any of claims 41-44, wherein R4 comprises

### Claim 46 (depends on 41, 42, 43, 44, 45)

The compound of any of claims 41-45, wherein R4 is

### Claim 47

The compound of any one of the preceding claims, wherein m is 5.

### Claim 48

The compound of any one of the preceding claims, wherein n is 2.

### Claim 49

The compound of any one of the preceding claims, wherein p is 2.

### Claim 50

The compound of any one of the preceding claims, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof, wherein the at least one radioisotope is 11C, 18F, 13N, 15O, 64Cu, 67Cu, 67Ga, 68Ga, 75Se, 81mKr, 82Rb, 99mTc, 111In, 123I, 125I, 131I, or 133Xe.

### Claim 51

The compound of any one of the preceding claims, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof, wherein the at least one radioisotope is 11C, 18F, 13N, 15O, 75Se, 123I, 125I, or 131I.

### Claim 52

The compound of any one of the preceding claims, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof, wherein the radioisotope is 18F.

### Claim 53

The compound of any one of the preceding claims, wherein the compound is of formula:
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof.

### Claim 54

The compound of any one of the preceding claims, wherein the compound degrades less than 10% one hour after preparing the compound.

### Claim 55

The compound of any one of the preceding claims, wherein the compound degrades less than 10% two hours after preparing the compound.

### Claim 56

A pharmaceutical composition comprising:
the compound of any one of the preceding claims, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof; and
a pharmaceutically acceptable excipient.

### Claim 57 (depends on 56)

The pharmaceutical composition of claim 56 further comprising one or more additional pharmaceutical agents.

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

A method of diagnosing a disease in a subject in need thereof comprising administering to the subject an effective amount of:
the compound of any one of claims 1-55, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof; or
the pharmaceutical composition of any one of claim 56 or 57.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The compound of any one of claims 1-55, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof, or the pharmaceutical composition of any one of claim 56 or 57, for use in diagnosing a disease in a subject in need thereof.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The compound of any one of claims 1-55, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof, or the pharmaceutical composition of any one of claim 56 or 57, for use in the manufacture of a medicament for diagnosis of a disease in a subject in need thereof.

### Claim 61 (depends on 58, 59, 60)

The method or compound for use, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof for use, or pharmaceutical composition for use of any one of claims 58-60, comprising imaging a tissue.

### Claim 62 (depends on 58, 59, 60, 61)

The method or compound for use, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof for use, or pharmaceutical composition for use of any one of claims 58-61, comprising imaging liver tissue.

### Claim 63 (depends on 58, 59, 60, 61, 62)

The method or compound for use, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof for use, or pharmaceutical composition for use of any one of claims 58-62, comprising imaging through positron emission tomography (PET).

### Claim 64 (depends on 58, 59, 60, 61, 62, 63)

The method or compound for use, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof for use, or pharmaceutical composition for use of any one of claims 58-63, comprising imaging through computed tomography (CT).

### Claim 65 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

A method of treating a disease in a subject in need thereof comprising administering to the subject an effective amount of:
the compound of any one of claims 1-55, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof; or
the pharmaceutical composition of any one of claim 56 or 57.

### Claim 66 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The compound of any one of claims 1-55, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof, or the pharmaceutical composition of any one of claim 56 or 57, for use in treating a disease in a subject in need thereof.

### Claim 67 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The compound of any one of claims 1-55, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof, or the pharmaceutical composition of any one of claim 56 or 57, for use in the manufacture of a medicament for treatment of a disease in a subject in need thereof.

### Claim 68 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

A method of preventing a disease in a subject in need thereof comprising administering to the subject an effective amount of:
the compound of any one of claims 1-55, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof; or
the pharmaceutical composition of any one of claim 56 or 57.

### Claim 69 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The compound of any one of claims 1-55, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof, or the pharmaceutical composition of any one of claim 56 or 57, for use in preventing a disease in a subject in need thereof.

### Claim 70 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The compound of any one of claims 1-55, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof, or the pharmaceutical composition of any one of claim 56 or 57, for use in the manufacture of a medicament for prevention of a disease in a subject in need thereof.

### Claim 71 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

A method of inhibiting cell proliferation or promoting apoptosis in a subject in need thereof or in a cell, tissue, or biological sample, comprising administering to the subject or contacting the cell, tissue, or biological sample with an effective amount of:
the compound of any one of claims 1-55, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof; or
the pharmaceutical composition of any one of claim 56 or 57;
wherein the cell, tissue, or biological sample is in vivo.

### Claim 72 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

A method of inhibiting cell proliferation or promoting apoptosis in a subject in need thereof or in a cell, tissue, or biological sample, comprising administering to the subject or contacting the cell, tissue, or biological sample with an effective amount of:
the compound of any one of claims 1-55, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof; or
the pharmaceutical composition of any one of claim 56 or 57;
wherein the cell, tissue, or biological sample is in vitro.

### Claim 73 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

A method of imaging a subject in need thereof comprising administering to the subject an effective amount of:
the compound of any one of claims 1-55, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof; or
the pharmaceutical composition of any one of claim 56 or 57; and
detecting the at least one radioisotope.

### Claim 74 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The compound of any one of claims 1-55, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof, or the pharmaceutical composition of any one of claim 56 or 57, for use in diagnosing a disease in a subject in need thereof.

### Claim 75 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The compound of any one of claims 1-55, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof, or the pharmaceutical composition of any one of claim 56 or 57, for use in the manufacture of a medicament for diagnosis of a disease in a subject in need thereof.

### Claim 76 (depends on 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75)

The method or compound for use, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof for use, or pharmaceutical composition for use of any one of claims 58-75, wherein the disease is a cancer.

### Claim 77 (depends on 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

The method or compound for use, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof for use, or pharmaceutical composition for use of any one of claims 58-76, wherein the disease is liver cancer.

### Claim 78 (depends on 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

The method or compound for use, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof for use, or pharmaceutical composition for use of any one of claims 58-77, wherein the liver cancer is hepatocellular carcinoma (HCC).

### Claim 79 (depends on 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The method or compound for use, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof for use, or pharmaceutical composition for use of any one of claims 58-78, wherein the subject is a human.

### Claim 80 (depends on 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

The method or compound for use, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof for use, or pharmaceutical composition for use of any one of claims 58-79, wherein the subject has been administered one or more additional pharmaceutical agents and/or radiation.

### Claim 81 (depends on 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80)

The method or compound for use, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof for use, or pharmaceutical composition for use of any one of claims 58-80, wherein the subject suffers from underlying liver disease, chronic hepatitis, and/or cirrhosis.

### Claim 82 (depends on 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

The method or compound for use, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof for use, or pharmaceutical composition for use of any one of claims 58-81, wherein the compound is detected in the liver within 15 minutes of administration, within 30 minutes of administration, within 45 minutes of administration, within 1 hour of administration, within 2 hours of administration, within 3 hours of administration, or within 4 hours of administration.

### Claim 83 (depends on 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82)

The method or compound for use, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof for use, or pharmaceutical composition for use of any one of claims 58-82, wherein the activity concentration, as measured by standardized uptake value (SUV), in the liver after administration is at least 5, at least 10, at least 15, at least 20, or at least 25.

### Claim 84 (depends on 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

The method or compound for use, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof for use, or pharmaceutical composition for use of any one of claims 58-83, wherein the activity uptake, as measured by percentage injected dose (% ID), in the liver after administration is at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, or at least about 99%.

### Claim 85

A method of preparing a compound of Formula I-g-i:
or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof, the method comprising reacting an amine of Formula I-f-ii:
or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof, with a compound of Formula II:
or salt thereof, wherein:
each occurrence of R2 is independently hydrogen, halogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two occurrences of R2 are joined together with their intervening atom to form an optionally substituted carbocyclic ring or optionally substituted heterocyclic ring;
Rb1 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, and contains at least one radioisotope;
Rb2 is halogen or —ORA;
RA is independently hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and
n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

### Claim 86 (depends on 85)

The method of claim 85, wherein the compound of Formula II is an activated ester of Formula II-a or Formula II-b:
or salt thereof.

### Claim 87 (depends on 85, 86)

The method of any one of claim 85 or 86, further comprising converting an ester of Formula II-c:
or salt thereof, to an activated ester of Formula II-a or Formula II-b:
or salt thereof.

### Claim 88 (depends on 85, 86, 87)

The method of any one of claims 85-87, comprising reacting the ester of formula II-c:
or salt thereof, with 2-(2,5-dioxopyrrolidin-1-yl)-1,1,3,3-tetramethylisouronium tetrafluoroborate (TSTU) to provide the activated ester of Formula II-a:
or salt thereof.

### Claim 89 (depends on 85, 86, 87, 88)

The method of any one of claims 85-88, further comprising reacting a compound of Formula II-d:
or salt thereof, with 18F− to provide a compound of Formula II-e:
or salt thereof, wherein:
LG is a leaving group.

### Claim 90 (depends on 89)

The method of claim 89, wherein the leaving group is NMe3.

### Claim 91 (depends on 89, 90)

The method of any one of claim 89 or 90, wherein reacting the compound of Formula II-d with 18F− comprises adding [18F]KF/K222.

### Claim 92 (depends on 89, 90)

The method of any one of claim 89 or 90, wherein reacting the compound of Formula II-d with 18F− comprises adding [18F]TBAF.

### Claim 93 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

A kit comprising:
the compound of any one of claims 1-55, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof; or the pharmaceutical composition of any one of claim 56 or 57; and
instructions for using the compound, or pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or prodrug thereof, or pharmaceutical composition.
